{"bundle_type":"pith_open_graph_bundle","bundle_version":"1.0","pith_number":"pith:2013:FDAFNWVVYPRASEFES6CL6J4QHY","short_pith_number":"pith:FDAFNWVV","canonical_record":{"source":{"id":"1309.5019","kind":"arxiv","version":1},"metadata":{"license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","primary_cat":"stat.ME","submitted_at":"2013-09-19T15:24:51Z","cross_cats_sorted":[],"title_canon_sha256":"da9bc67663d3323ac83b6f00b306d2dadc3c372c83f5ca3804456dcd9420e4ca","abstract_canon_sha256":"35f54bb6089ace172982db71f60ac1b9e613d39486a3e7d8ef7c4e55b1a8e299"},"schema_version":"1.0"},"canonical_sha256":"28c056dab5c3e20910a49784bf27903e00ea3b3a2cc8149ad348a6c13b427baa","source":{"kind":"arxiv","id":"1309.5019","version":1},"source_aliases":[{"alias_kind":"arxiv","alias_value":"1309.5019","created_at":"2026-05-18T03:12:49Z"},{"alias_kind":"arxiv_version","alias_value":"1309.5019v1","created_at":"2026-05-18T03:12:49Z"},{"alias_kind":"doi","alias_value":"10.48550/arxiv.1309.5019","created_at":"2026-05-18T03:12:49Z"},{"alias_kind":"pith_short_12","alias_value":"FDAFNWVVYPRA","created_at":"2026-05-18T12:27:45Z"},{"alias_kind":"pith_short_16","alias_value":"FDAFNWVVYPRASEFE","created_at":"2026-05-18T12:27:45Z"},{"alias_kind":"pith_short_8","alias_value":"FDAFNWVV","created_at":"2026-05-18T12:27:45Z"}],"events":[{"event_type":"record_created","subject_pith_number":"pith:2013:FDAFNWVVYPRASEFES6CL6J4QHY","target":"record","payload":{"canonical_record":{"source":{"id":"1309.5019","kind":"arxiv","version":1},"metadata":{"license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","primary_cat":"stat.ME","submitted_at":"2013-09-19T15:24:51Z","cross_cats_sorted":[],"title_canon_sha256":"da9bc67663d3323ac83b6f00b306d2dadc3c372c83f5ca3804456dcd9420e4ca","abstract_canon_sha256":"35f54bb6089ace172982db71f60ac1b9e613d39486a3e7d8ef7c4e55b1a8e299"},"schema_version":"1.0"},"canonical_sha256":"28c056dab5c3e20910a49784bf27903e00ea3b3a2cc8149ad348a6c13b427baa","receipt":{"kind":"pith_receipt","key_id":"pith-v1-2026-05","algorithm":"ed25519","signed_at":"2026-05-18T03:12:49.054184Z","signature_b64":"TP9asxwpHCx9uOpyyY4AvMyHGAPdjRQjToGZCuF0+AUtjQ/1pauDto1RqPW2mLVvyUFXSCEK40h8R6q2r1/5CA==","signed_message":"canonical_sha256_bytes","builder_version":"pith-number-builder-2026-05-17-v1","receipt_version":"0.3","canonical_sha256":"28c056dab5c3e20910a49784bf27903e00ea3b3a2cc8149ad348a6c13b427baa","last_reissued_at":"2026-05-18T03:12:49.053663Z","signature_status":"signed_v1","first_computed_at":"2026-05-18T03:12:49.053663Z","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54"},"source_kind":"arxiv","source_id":"1309.5019","source_version":1,"attestation_state":"computed"},"signer":{"signer_id":"pith.science","signer_type":"pith_registry","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54"},"created_at":"2026-05-18T03:12:49Z","supersedes":[],"prev_event":null,"signature":{"signature_status":"signed_v1","algorithm":"ed25519","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signature_b64":"04ZsTyr5zpWAJUr6ePtMUF0WGEEV02ftyRK/kmi+hQinFe5CR1G8/F5u1nyMSEF/bXOM3WEHJ4Z1/XQC0mzSDA==","signed_message":"open_graph_event_sha256_bytes","signed_at":"2026-06-20T08:17:50.467677Z"},"content_sha256":"f6b0da28f2c8926ced915c685388950d44502ad258a7742a2dd91ec3211236ca","schema_version":"1.0","event_id":"sha256:f6b0da28f2c8926ced915c685388950d44502ad258a7742a2dd91ec3211236ca"},{"event_type":"graph_snapshot","subject_pith_number":"pith:2013:FDAFNWVVYPRASEFES6CL6J4QHY","target":"graph","payload":{"graph_snapshot":{"paper":{"title":"Bayesian Decision-optimal Interval Designs for Phase I Clinical Trials","license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","headline":"","cross_cats":[],"primary_cat":"stat.ME","authors_text":"Suyu Liu, Ying Yuan","submitted_at":"2013-09-19T15:24:51Z","abstract_excerpt":"Interval designs are a class of phase I trial designs for which the decision of dose assignment is determined by comparing the observed toxicity rate at the current dose with a prespecified (toxicity tolerance) interval. If the observed toxicity rate is located within the interval, we retain the current dose; if the observed toxicity rate is greater than the upper boundary of the interval, we deescalate the dose; and if the observed toxicity rate is smaller than the lower boundary of the interval, we escalate the dose. The most critical issue for the interval design is choosing an appropriate "},"claims":{"count":0,"items":[],"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"source":{"id":"1309.5019","kind":"arxiv","version":1},"verdict":{"id":null,"model_set":{},"created_at":null,"strongest_claim":"","one_line_summary":"","pipeline_version":null,"weakest_assumption":"","pith_extraction_headline":""},"references":{"count":0,"sample":[],"resolved_work":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57","internal_anchors":0},"formal_canon":{"evidence_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"author_claims":{"count":0,"strong_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"builder_version":"pith-number-builder-2026-05-17-v1"},"verdict_id":null},"signer":{"signer_id":"pith.science","signer_type":"pith_registry","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54"},"created_at":"2026-05-18T03:12:49Z","supersedes":[],"prev_event":null,"signature":{"signature_status":"signed_v1","algorithm":"ed25519","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signature_b64":"2Ty4VRDnEl5ZKJGYgOobTZnGGwKBam+kxt/ys/H/GLAEyEIy+z/dc+8DgCZ/XF1Ls3f9da24efolKR6kLwIIDg==","signed_message":"open_graph_event_sha256_bytes","signed_at":"2026-06-20T08:17:50.468008Z"},"content_sha256":"d6ddf5633aef3cb43f62e3b5d35799d1cd20be6cf69070cfb381713bb278feab","schema_version":"1.0","event_id":"sha256:d6ddf5633aef3cb43f62e3b5d35799d1cd20be6cf69070cfb381713bb278feab"}],"timestamp_proofs":[],"mirror_hints":[{"mirror_type":"https","name":"Pith Resolver","base_url":"https://pith.science","bundle_url":"https://pith.science/pith/FDAFNWVVYPRASEFES6CL6J4QHY/bundle.json","state_url":"https://pith.science/pith/FDAFNWVVYPRASEFES6CL6J4QHY/state.json","well_known_bundle_url":"https://pith.science/.well-known/pith/FDAFNWVVYPRASEFES6CL6J4QHY/bundle.json","status":"primary"}],"public_keys":[{"key_id":"pith-v1-2026-05","algorithm":"ed25519","format":"raw","public_key_b64":"stVStoiQhXFxp4s2pdzPNoqVNBMojDU/fJ2db5S3CbM=","public_key_hex":"b2d552b68890857171a78b36a5dccf368a953413288c353f7c9d9d6f94b709b3","fingerprint_sha256_b32_first128bits":"RVFV5Z2OI2J3ZUO7ERDEBCYNKS","fingerprint_sha256_hex":"8d4b5ee74e4693bcd1df2446408b0d54","rotates_at":null,"url":"https://pith.science/pith-signing-key.json","notes":"Pith uses this Ed25519 key to sign canonical record SHA-256 digests. Verify with: ed25519_verify(public_key, message=canonical_sha256_bytes, signature=base64decode(signature_b64))."}],"merge_version":"pith-open-graph-merge-v1","built_at":"2026-06-20T08:17:50Z","links":{"resolver":"https://pith.science/pith/FDAFNWVVYPRASEFES6CL6J4QHY","bundle":"https://pith.science/pith/FDAFNWVVYPRASEFES6CL6J4QHY/bundle.json","state":"https://pith.science/pith/FDAFNWVVYPRASEFES6CL6J4QHY/state.json","well_known_bundle":"https://pith.science/.well-known/pith/FDAFNWVVYPRASEFES6CL6J4QHY/bundle.json"},"state":{"state_type":"pith_open_graph_state","state_version":"1.0","pith_number":"pith:2013:FDAFNWVVYPRASEFES6CL6J4QHY","merge_version":"pith-open-graph-merge-v1","event_count":2,"valid_event_count":2,"invalid_event_count":0,"equivocation_count":0,"current":{"canonical_record":{"metadata":{"abstract_canon_sha256":"35f54bb6089ace172982db71f60ac1b9e613d39486a3e7d8ef7c4e55b1a8e299","cross_cats_sorted":[],"license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","primary_cat":"stat.ME","submitted_at":"2013-09-19T15:24:51Z","title_canon_sha256":"da9bc67663d3323ac83b6f00b306d2dadc3c372c83f5ca3804456dcd9420e4ca"},"schema_version":"1.0","source":{"id":"1309.5019","kind":"arxiv","version":1}},"source_aliases":[{"alias_kind":"arxiv","alias_value":"1309.5019","created_at":"2026-05-18T03:12:49Z"},{"alias_kind":"arxiv_version","alias_value":"1309.5019v1","created_at":"2026-05-18T03:12:49Z"},{"alias_kind":"doi","alias_value":"10.48550/arxiv.1309.5019","created_at":"2026-05-18T03:12:49Z"},{"alias_kind":"pith_short_12","alias_value":"FDAFNWVVYPRA","created_at":"2026-05-18T12:27:45Z"},{"alias_kind":"pith_short_16","alias_value":"FDAFNWVVYPRASEFE","created_at":"2026-05-18T12:27:45Z"},{"alias_kind":"pith_short_8","alias_value":"FDAFNWVV","created_at":"2026-05-18T12:27:45Z"}],"graph_snapshots":[{"event_id":"sha256:d6ddf5633aef3cb43f62e3b5d35799d1cd20be6cf69070cfb381713bb278feab","target":"graph","created_at":"2026-05-18T03:12:49Z","signer":{"key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signer_id":"pith.science","signer_type":"pith_registry"},"payload":{"graph_snapshot":{"author_claims":{"count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57","strong_count":0},"builder_version":"pith-number-builder-2026-05-17-v1","claims":{"count":0,"items":[],"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"formal_canon":{"evidence_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"paper":{"abstract_excerpt":"Interval designs are a class of phase I trial designs for which the decision of dose assignment is determined by comparing the observed toxicity rate at the current dose with a prespecified (toxicity tolerance) interval. If the observed toxicity rate is located within the interval, we retain the current dose; if the observed toxicity rate is greater than the upper boundary of the interval, we deescalate the dose; and if the observed toxicity rate is smaller than the lower boundary of the interval, we escalate the dose. The most critical issue for the interval design is choosing an appropriate ","authors_text":"Suyu Liu, Ying Yuan","cross_cats":[],"headline":"","license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","primary_cat":"stat.ME","submitted_at":"2013-09-19T15:24:51Z","title":"Bayesian Decision-optimal Interval Designs for Phase I Clinical Trials"},"references":{"count":0,"internal_anchors":0,"resolved_work":0,"sample":[],"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"source":{"id":"1309.5019","kind":"arxiv","version":1},"verdict":{"created_at":null,"id":null,"model_set":{},"one_line_summary":"","pipeline_version":null,"pith_extraction_headline":"","strongest_claim":"","weakest_assumption":""}},"verdict_id":null}}],"author_attestations":[],"timestamp_anchors":[],"storage_attestations":[],"citation_signatures":[],"replication_records":[],"corrections":[],"mirror_hints":[],"record_created":{"event_id":"sha256:f6b0da28f2c8926ced915c685388950d44502ad258a7742a2dd91ec3211236ca","target":"record","created_at":"2026-05-18T03:12:49Z","signer":{"key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signer_id":"pith.science","signer_type":"pith_registry"},"payload":{"attestation_state":"computed","canonical_record":{"metadata":{"abstract_canon_sha256":"35f54bb6089ace172982db71f60ac1b9e613d39486a3e7d8ef7c4e55b1a8e299","cross_cats_sorted":[],"license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","primary_cat":"stat.ME","submitted_at":"2013-09-19T15:24:51Z","title_canon_sha256":"da9bc67663d3323ac83b6f00b306d2dadc3c372c83f5ca3804456dcd9420e4ca"},"schema_version":"1.0","source":{"id":"1309.5019","kind":"arxiv","version":1}},"canonical_sha256":"28c056dab5c3e20910a49784bf27903e00ea3b3a2cc8149ad348a6c13b427baa","receipt":{"algorithm":"ed25519","builder_version":"pith-number-builder-2026-05-17-v1","canonical_sha256":"28c056dab5c3e20910a49784bf27903e00ea3b3a2cc8149ad348a6c13b427baa","first_computed_at":"2026-05-18T03:12:49.053663Z","key_id":"pith-v1-2026-05","kind":"pith_receipt","last_reissued_at":"2026-05-18T03:12:49.053663Z","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","receipt_version":"0.3","signature_b64":"TP9asxwpHCx9uOpyyY4AvMyHGAPdjRQjToGZCuF0+AUtjQ/1pauDto1RqPW2mLVvyUFXSCEK40h8R6q2r1/5CA==","signature_status":"signed_v1","signed_at":"2026-05-18T03:12:49.054184Z","signed_message":"canonical_sha256_bytes"},"source_id":"1309.5019","source_kind":"arxiv","source_version":1}}},"equivocations":[],"invalid_events":[],"applied_event_ids":["sha256:f6b0da28f2c8926ced915c685388950d44502ad258a7742a2dd91ec3211236ca","sha256:d6ddf5633aef3cb43f62e3b5d35799d1cd20be6cf69070cfb381713bb278feab"],"state_sha256":"e5a416a32a392200d9d4742c349beca302974f8438015ef7b037fabf3400a32d"},"bundle_signature":{"signature_status":"signed_v1","algorithm":"ed25519","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signature_b64":"H6QJAQQcRNvr2k6hDbFvDEuwj2li/no3onL79FKvUF1s5YXat+mtznLSwThIMh3mMu+yzt9fjoXhzWWUnlafDg==","signed_message":"bundle_sha256_bytes","signed_at":"2026-06-20T08:17:50.469925Z","bundle_sha256":"15d2d2a03dace446318eeb8de23b5f43e5db302777225cea4910b90fb4d96adf"}}